Disposable Bioreactors for Viral Vaccine Production: Challenges and Opportunities - Switching to single-use bioreactors can have financial and performance benefits. - BioPharm International

ADVERTISEMENT

Disposable Bioreactors for Viral Vaccine Production: Challenges and Opportunities
Switching to single-use bioreactors can have financial and performance benefits.


BioPharm International Supplements


Risk Assessments

Disposable bioreactors are a new technology in the biotechnology field. To evaluate potential risks associated with implementing this new technology in future manufacturing processes, risk assessments based on the FMEA methodology were performed. The main risk assessments performed were related to the two critical risks: assurance of supply, and biosafety, a risk specific to viral vaccine applications. The biosafety risk assessment will be used as an example.

Biosafety is one of the main concerns of viral vaccine production, especially when biosafety level 2 and 3 viruses must be produced at large scale. One concept of biosafety is that the equipment itself is considered the first barrier to isolate the pathogenic micro-organism from the environment. The second barrier is the room where the equipment is located. The move from stainless steel to disposable equipment has weakened the first barrier. The main problem in terms of biosafety is the loss of integrity of the disposable bag leading to a leak of the viral contaminant, and potentially operator contamination. To identify all potential root causes for the loss of integrity of the disposable bioreactor, a risk assessment was conducted. Risks were scored according to four criteria, each scaled from 1 to 3: impact, occurrence, detection, and action response time. A risk priority number (RPN) was calculated as the multiplication of these four criteria. Based on the associated RPN, risks were classified as follows:

  • 1 to 3 RPN: low risk
  • 4 to 6 RPN from: medium risk
  • >7 RPN: high risk.

Figure 7 gives a summary of the risks identified associated with their respective RPN. Based on this risk assessment, a set of corrective actions were defined. The following gives examples of improvements made to the systems to mitigate potential biosafety issues:
  • automation, aeration, and pump stops when an overpressure is detected
  • external protection was developed to avoid liquid projections in case of leak and to avoid contact with cutting objects
  • a retention vessel will be part of the system skid to keep the liquid contained in case of spill
  • integrity testing of the disposable bag is under development using pressure to detect bag defaults.


Figure 7. Summary of biosafety risk assessment and associated risk priority numbers
Implementing all of the corrective actions identified in the risk assessment will help secure the disposable system for manufacturing operations.

Cost of Goods

Most of the studies performed today are in favor of disposable implementation from a cost perspective. Despite this, two scenarios should be considered in which the effect of disposable use on cost can be significantly different.

  • Introducing disposables to an existing process in an existing facility.
  • Introducing disposables to a new facility.

In the first scenario (existing facility), the effect of disposables may be marginal and can sometimes even result in increased cost of goods. The reason is that savings linked to disposable implementation are minimized because operating costs are fixed. Costs linked to full time employees will not be affected because production teams are in place. Building depreciation and maintenance also will be equivalent.

In the second scenario (new facility), the effect of implementing disposables can be more significant if the new facility is designed for using disposables. In this case, the facility footprint can be significantly reduced, utility sizing and distribution can be minimized, and production headcount can be adjusted.

At GSK Biologicals, we decided to compare two greenfield manufacturing plants for viral bulk production, one using the old process as a reference, the other one using a similar process but implementing disposable bioreactors along with other disposable systems for media and buffer preparations and purification intermediates. It is important to mention that the manufacturing scheduling was changed along with disposable bioreactor implementation. This point has a major effect on costs.

The model used to make this cost calculation was developed in-house and was validated on existing marketed vaccines. The first component of the cost analysis was establishing a bill of material analysis. Regarding the new process, 50% of the raw material cost was linked to the medium, ~25% was linked to micro-carriers, and the disposable bioreactor represents 6% of our raw material cost.

The output of our model shows that 35% can be saved on facility investment, and the manufacturing headcount (production and maintenance) can be reduced by 30%. If we consider the effect on total direct cost, 25% can be saved on the cost per dose driven by saving on building depreciation and labor. As mentioned previously, a significant amount (~50%) of the savings are linked to the optimization of manufacturing scheduling.

Conclusion

We demonstrated the feasibility to achieve equivalent process performance using the right disposable bioreactor systems compared to stainless steel bioreactors, even in the case of challenging processes, such as the one described in this article.

Additionally, cost of goods analyses show a significant savings when disposable technologies are implemented in new facilities, along with redesigning the manufacturing schedule.

Disposable bioreactors are an attractive technology for viral vaccine production if biosafety risk can be mitigated. One major point is that supply assurance is still a major problem because back-up supply is difficult to establish because of the specificity of these disposable bioreactors.

Jean-François Chaubard is a director, Sandrine Dessoy and Yves Ghislain are expert scientists, Benoit Barbier and Raphael Battisti are technicians, and Pascal Gerkens, PhD, and Ludovic Peeters are associate scientists, all at Viral Industrial Bulk, GSK Biologicals, Rixensart, Belgium,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here